• Profile

Randomized placebo‐controlled trial of losartan for pediatric nonalcoholic fatty liver disease

Hepatology Feb 11, 2022

In pediatric nonalcoholic fatty liver disease (NAFLD) cases, no significant decrease in alanine aminotransferase (ALT) was achieved with losartan (an angiotensin II receptor blocker) than placebo in this study.

  • In a multicenter, double-masked, placebo-controlled, randomized clinical trial, 83 eligible children with histologically-confirmed NAFLD (81% male, 80% Hispanic) were randomized to losartan (n=43) or placebo (n=40).

  • No significant difference in “24-week ALT change” was found between losartan vs placebo groups (adjusted mean difference: 1.1 U/L), although a significant reduction in alkaline phosphatase was noted in the losartan group (adjusted mean difference: -23.4 U/L).

  • Decline in systolic blood pressure in the losartan group but elevation in placebo group was evident (adjusted mean difference: -7.5 mmHg).

  • Between groups, compliance by pill counts and numbers and types of adverse events did not vary.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen